Results 51 to 60 of about 15,628 (311)

Adverse event profile of crizotinib in real-world from the FAERS database: a 12-year pharmacovigilance study

open access: yesBMC Pharmacology and Toxicology
Crizotinib, an anaplastic lymphoma kinase tyrosine kinase inhibitor (ALK-TKI). It gained approval from the U.S. Food and Drug Administration (FDA) specifically for treating ALK-positive non-small cell lung cancer (NSCLC).
Huan Zhang   +9 more
semanticscholar   +1 more source

Pediatric Developmental Safety Assessment: Are We Ready for the Next Thalidomide?

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Pediatric drug development has achieved remarkable success in the last 20 years with over 1,000 products studied in pediatric patients. This success has been driven in part by an increased understanding of pediatric disease processes. The aspect that has been largely overlooked is the potential adverse effect of new drugs on pediatric developmental ...
Gilbert J. Burckart   +6 more
wiley   +1 more source

Identification and Mechanistic Investigation of Drug-Drug Interactions Associated With Myopathy: A Translational Approach [PDF]

open access: yes, 2015
Myopathy is a group of muscle diseases that can be induced or exacerbated by drug-drug interactions (DDIs). We sought to identify clinically important myopathic DDIs and elucidate their underlying mechanisms.
Desta, Z.   +8 more
core   +1 more source

Major Adverse Cardiac Events with Ondansetron: A Systematic Review

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Evidence base: 170 randomized trials, 23,421 adults, predominantly single‐dose IV ondansetron, mean follow‐up 20 days. Observed outcomes: Major adverse cardiac events were rare, no ventricular arrhythmias or torsades de pointes observed. Conclusion: Ondansetron was not associated with increased mortality or serious cardiac arrhythmias in adult ...
Michael Cristian Garcia   +11 more
wiley   +1 more source

Relationship between thromboembolic events and thrombopoietin receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System and the Japanese Adverse Drug Event Report

open access: yesBMJ Open
Objective Thrombopoietin receptor agonists (TPO-RAs) are widely used in thrombocytopenia, yet their association with thromboembolic events (TEEs) remains concerning.
Zheng Wang   +5 more
doaj   +1 more source

Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory. [PDF]

open access: yes, 2019
Proton-pump inhibitors, PPIs, are considered effective therapy for stomach acid suppression due to their irreversible inhibition of the hydrogen/potassium pump in the gastric parietal cells. They are widely prescribed and are considered safe for over-the-
Abagyan, Ruben   +4 more
core   +1 more source

Gels under stress: the origins of delayed collapse

open access: yes, 2014
Attractive colloidal particles can form a disordered elastic solid or gel when quenched into a two-phase region, if the volume fraction is sufficiently large.
Bartlett, Paul   +5 more
core   +1 more source

Detecting associations between behavioral addictions and dopamine agonists in the Food & Drug Administration's Adverse Event database [PDF]

open access: yes, 2014
Background/Aims Studies have reported higher prevalences of four behavioral addictions (binge eating, compulsive shopping, hypersexuality, and pathological gambling) in dopamine agonist-treated Parkinson's disease relative to non-dopamine agonist ...
Gendreau, Katherine E., Potenza, Marc N.
core   +2 more sources

Sex‐specific elevated incidence of glaucoma associated with topiramate versus valproate or lamotrigine in epilepsy, not migraine: A population‐based cohort study

open access: yesEpilepsia, EarlyView.
Abstract Objective Topiramate has been linked to increased glaucoma risk, potentially through mechanisms involving ocular fluid shifts. However, comparative risks vs other antiseizure medications (ASMs) and variation by sex or indication remain uncertain.
Cuiling Wei   +10 more
wiley   +1 more source

Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database

open access: yesFrontiers in Pharmacology
Background: Pancreatitis is characterized by inflammation of the pancreas and significantly affects quality of life. Less than 5% of pancreatitis cases are drug-induced, but recent evidence suggests a substantial risk associated with glucagon-like ...
K. Alenzi   +3 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy